Marshall Wace, LLP Astrazeneca PLC Transaction History

Marshall Wace, LLP

$63.3 Billion
Q1 2024

A detailed history of Marshall Wace, LLP transactions in Astrazeneca PLC stock. As of the latest transaction made, Marshall Wace, LLP holds 1,145,637 shares of AZN stock, worth $89.3 Million. This represents 0.12% of its overall portfolio holdings.

Number of Shares

1,145,637

Previous 40,773 2709.79%

Holding current value

$89.3 Million

Previous $2.75 Million 2726.51%

% of portfolio

0.12%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$61.03 - $69.57 $67.4 Million - $76.9 Million	1,104,864 Added 2709.79%	1,145,637 $77.6 Million
Q4 2023 Feb 14, 2024	BUY	$61.89 - $69.28 $518,143 - $580,012	8,372 Added 25.84%	40,773 $2.75 Million
Q3 2023 Nov 14, 2023	SELL	$64.85 - $71.7 $13 Million - $14.4 Million	-200,513 Reduced 86.09%	32,401 $2.19 Million
Q2 2023 Aug 14, 2023	SELL	$69.91 - $75.81 $15.7 Million - $17 Million	-224,235 Reduced 49.05%	232,914 $16.7 Million
Q1 2023 May 15, 2023	SELL	$63.15 - $71.6 $119 Million - $135 Million	-1,880,091 Reduced 80.44%	457,149 $31.7 Million

Q4 2022 Feb 14, 2023	BUY	$54.21 - $70.44 $28.9 Million - $37.6 Million	533,909 Added 29.61%	2,337,240 $158 Million
Q3 2022 Nov 14, 2022	BUY	$53.02 - $135.75 $16.3 Million - $41.8 Million	307,566 Added 20.56%	1,803,331 $98.9 Million
Q2 2022 Aug 15, 2022	SELL	$59.26 - $71.14 $27 Million - $32.4 Million	-454,954 Reduced 23.32%	1,495,765 $98.8 Million
Q1 2022 May 16, 2022	SELL	$55.72 - $67.12 $4.87 Million - $5.87 Million	-87,399 Reduced 4.29%	1,950,719 $129 Million
Q4 2021 Feb 14, 2022	BUY	$54.02 - $63.83 $99.1 Million - $117 Million	1,834,202 Added 899.49%	2,038,118 $119 Million
Q3 2021 Nov 15, 2021	BUY	$55.56 - $60.79 $6.68 Million - $7.31 Million	120,255 Added 143.74%	203,916 $12.2 Million
Q2 2021 Aug 13, 2021	SELL	$48.42 - $60.18 $5.14 Million - $6.38 Million	-106,084 Reduced 55.91%	83,661 $5.01 Million
Q1 2021 May 17, 2021	BUY	$47.16 - $54.44 $7.47 Million - $8.62 Million	158,301 Added 503.44%	189,745 $9.43 Million
Q4 2020 Feb 16, 2021	BUY	$48.52 - $58.02 $1.53 Million - $1.82 Million	31,444 New	31,444 $1.57 Million
Q3 2020 Nov 16, 2020	SELL	$53.07 - $61.1 $7.71 Million - $8.87 Million	-145,242 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$43.1 - $55.31 $2.96 Million - $3.8 Million	68,786 Added 89.97%	145,242 $7.68 Million
Q1 2020 May 15, 2020	SELL	$37.79 - $51.33 $38.8 Million - $52.7 Million	-1,025,736 Reduced 93.06%	76,456 $3.41 Million
Q4 2019 Feb 14, 2020	SELL	$42.46 - $50.46 $33.3 Million - $39.5 Million	-783,271 Reduced 41.54%	1,102,192 $55 Million
Q3 2019 Nov 14, 2019	SELL	$40.12 - $45.47 $18.5 Million - $20.9 Million	-459,947 Reduced 19.61%	1,885,463 $84 Million
Q2 2019 Aug 14, 2019	BUY	$37.28 - $41.68 $63.3 Million - $70.7 Million	1,697,224 Added 261.84%	2,345,410 $96.8 Million
Q1 2019 May 14, 2019	BUY	$35.49 - $43.02 $23 Million - $27.9 Million	648,186 New	648,186 $26.2 Million
Q3 2018 Nov 14, 2018	SELL	$34.76 - $39.72 $10.4 Million - $11.9 Million	-299,591 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$34.55 - $37.05 $10.4 Million - $11.1 Million	299,591 New	299,591 $10.5 Million

Others Institutions Holding AZN

# of Institutions

1,246

Shares Held

477M

Call Options Held

5.99M

Put Options Held

5.24M

View Full List

About ASTRAZENECA PLC

Ticker AZN
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 3,099,020,032
Market Cap $242B
Description
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...

More about AZN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Account

Marshall Wace, LLP Astrazeneca PLC Transaction History